Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Obsidian Therapeutics and three other pharmaceutical companies announced successful Series B raises to propel pipeline candidates further down the track toward clinical studies and approvals.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The procurement will expand its PCR-test portfolio capabilities in the ongoing fight against existing and emerging infectious diseases, including new COVID-19 variants of interest.
Durham, N.C.-based Precision BioSciences announced a license and collaboration deal with Philadelphia-based iECURE and described its clinical development plans.
The FDA stated that it could not determine if the use of lenzilumab in COVID patients outweighs the known and potential safety risks.
Paris-based Sanofi announced its Phase III PEGASUS clinical trial of rilzabrutinib for pemphigus failed to hit primary or key secondary endpoints.
The partnership combines the companies’ resources to focus on Axiomer, a technology that can edit single nucleotides in RNA in a specific and highly targeted manner.
Recently launched biotech company Immunai is pairing artificial intelligence and machine learning in an attempt to tailor treatments and improve patient outcomes.
Attralus Therapeutics has had a fresh set of faces shuffling into its executive suite in the past few months. And apparently with new leadership comes new funding opportunities.
The company aims to make RNA molecules visible and druggable – opening the door to study RNA-based diseases.
Scientists from different agencies and research facilities have turned to laboratory manufactured human mini-brains to study the onset and progression of Parkinson’s disease.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.